Chargement en cours...
An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function
Two previously conducted rivaroxaban studies showed that, separately, renal impairment (RI) and concomitant administration of erythromycin (P-glycoprotein and moderate cytochrome P450 3A4 [CYP3A4] inhibitor) can result in increases in rivaroxaban exposure. However, these studies did not assess the p...
Enregistré dans:
| Publié dans: | J Clin Pharmacol |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BlackWell Publishing Ltd
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4241044/ https://ncbi.nlm.nih.gov/pubmed/24964176 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.352 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|